SLC5A2 and atrial fibrillation: If the positive short-term effects of SGLT-2 inhibitors, along with their favorable pharmacodynamics, are confirmed in AF models, this could encourage further investigation into their use as adjunctive therapy in clinical trials related to paroxysmal AF.